# NEXLIZET
> **NDA211617** · New Drug Application · Sponsor: ESPERION THERAPS INC · Approved 2020-02-26
## Drug
- **FDA Application Number:** NDA211617
- **Application type:** New Drug Application
- **Brand name:** NEXLIZET
- **Generic name:** BEMPEDOIC ACID AND EZETIMIBE
- **Active ingredients:** BEMPEDOIC ACID; EZETIMIBE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** ESPERION THERAPS INC
- **Manufacturer:** Esperion Therapeutics, Inc.
- **First approval:** 2020-02-26
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211617)
---
*MORVS · CC0 1.0*